J.B.CHEMICALS & PHARMACEUTICALS LTD.
P&L
Quarterly Consolidated
vs Q2 FY26
JB Chemicals & Pharmaceuticals Ltd Reports 11% Revenue Growth to INR 1065 Crores in Q3 FY26
16 Jan 2026 · 16 Jan, 6:23 pm
Summary
JB Chemicals & Pharmaceuticals Ltd, one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 31st December 2025. The company recorded a revenue of INR 1,065 crores, registering a growth of 11% from INR 963 crores in Q3 FY25. Operating EBITDA increased by 13% to INR 305 crores and Net Profit rose by 22% to INR 198 crores.
Key Highlights
- 1
Revenue of INR 1065 crores in Q3 FY26, registering growth of 11%
- 2
Operating EBITDA of INR 305 crores, a growth of 13%
- 3
Net Profit increased by 22% to INR 198 crores
- 4
Domestic formulations business outperformed the Indian pharmaceutical market
- 5
CDMO business continued its positive momentum
- 6
International formulations business recorded strong growth in several key markets
- 7
Improved operating margins for Q3 FY26 and 9M FY26
- 8
Strong balance sheet, net cash position, and sustained cash flow generation
- 9
Revenue of INR 3244 crores in 9M FY26, a growth of 9%
- 10
Operating EBITDA of INR 955 crores in 9M FY26, a growth of 13%
- 11
Profit after Tax registered growth of 18% to INR 608 crores in 9M FY26
- 12
Domestic formulations business recorded revenue of INR 620 crores vs INR 566 crores
- 13
International business revenue grew by 12% to INR 445 crores
- 14
Domestic and CDMO business revenue combined constitutes 70% of overall revenue for 9M FY26
Management Comments
Mr. Nikhil Chopra
CEO and Wholetime Director, JB Pharma
JB Pharma’s domestic formulations business, once again outperformed the Indian pharmaceutical market, driven by broad-based momentum across key chronic therapies and continued strength in our flagship brands. On the international front, while the CDMO business continued its positive momentum, the international formulations business also recorded strong growth in several key markets. Our focus on cost optimization, favourable product mix and operational efficiencies led to improved operating margins for Q3 FY26 as well as for 9M FY26. With a strong balance sheet, net cash position, and sustained cash flow generation, we remain confident in our ability to deliver profitable growth. As we move forward, our priorities remain centered on strengthening flagship brand franchises, accelerating growth in chronic therapies, scaling our CDMO businesses, and building a resilient, agile, and future-ready organization.
Informational and educational content only. Not investment advice.